MedTrace Logo

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

NCT06672549 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2026-05-19

No results posted yet for this study

Summary

The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

Conditions

Interventions

DRUG

Orforglipron

Administered orally. ISA specific interventions will be listed in the ISA.

DRUG

Placebo

Administered orally. ISA specific interventions will be listed in the ISA.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-18
Primary Completion
2027-02-28
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • Israel
  • Italy
  • Japan
  • Mexico
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06672549 on ClinicalTrials.gov